Evidence map›Paper›PMID 26470602›Full record

ReviewExpert review of gastroenterology & hepatology2015

Recent advances in the pathological understanding of eosinophilic esophagitis.

Antonella Cianferoni, Jonathan M Spergel, Amanda Muir

Abstract readReview
In one paragraph

Review in Expert review of gastroenterology & hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Eosinophilic esophagitis: early diagnosis is the key.Clinical and experimental gastroenterology · 2019
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Non-IgE-mediated food allergy syndromes.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2016
    Review
  15. Review
  16. Tests for Evaluating Eosinophilic Esophagitis.Gastroenterology & hepatology · 2015
    Article
  17. Review
  18. Eosinophilic Esophagitis: A Primary Disease of the Esophageal Mucosa.The journal of allergy and clinical immunology. In practice
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Antonella Cianferonia 1 Division of Allergy and Immunology, The Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA 19104, USA.
Jonathan M Spergela 1 Division of Allergy and Immunology, The Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA 19104, USA.
Amanda Muirb 2 Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
University of Pennsylvania · USChildren's Hospital of Philadelphia · US

Funding

TRAINING (CAREER DEVELOPMENT) COMPONENTU54AI117804 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI GLENN T FURUTA, Marc E. Rothenberg · 2014 to 2026
$18.5M
Lysyl oxidase mediated fibrosis in eosinophilic esophagitisK08DK106444 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI MUIR, AMANDA BROOKE · 2015 to 2019
$778k
NIAID NIH HHS U54 AI117804NIDDK NIH HHS K08 DK106444NIDDK NIH HHS K08DK106444
6 · The paper itself

Abstract

Eosinophilic esophagitis (EoE) is a chronic allergen-mediated inflammatory disease of the esophagus. This inflammation leads to feeding difficulties, failure to thrive and vomiting in young children, and causes food impaction and esophageal stricture in adolescents and adults. In the 20 years since EoE was first described, we have gained a great deal of knowledge regarding the genetic predisposition of disease, the inflammatory milieu associated with EoE and the long-term complications of chronic inflammation. Herein, we summarize the important breakthroughs in the field including both in vitro and in vivo analysis. We discuss insights that we have gained from large-scale unbiased genetic analysis, a multitude of genetically and chemically altered mouse models of EoE and most importantly, the results of clinical trials of various pharmacologic agents. Understanding these successes and failures may be the key to developing more effective therapeutic strategies.

Indexed as

AnimalsBasophilsCalpainCellular MicroenvironmentCytokinesDysbiosisEosinophilic EsophagitisEsophagusFibrosisGenetic Predisposition to DiseaseHumansImmunoglobulin EInterleukin-13Interleukin-5Mast CellsMucous MembraneCalpainCAPN14 protein, humanCRLF2 protein, humanCytokinesEMSY protein, humanImmunoglobulin EInterleukin-13Interleukin-5Neoplasm ProteinsNuclear ProteinsReceptors, CytokineRepressor ProteinsThymic Stromal Lymphopoietineosinophilic esophagitisfibrosisIL-13T cellsthymic stromal lymphopoietin

Identifiers

PMID26470602
PMCPMC4943572
OpenAlexW2218627298

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.